Leuko is an MIT spinout developing PointCheck, the world's first medical device that can monitor white blood cells non-invasively. By enabling more frequent and at-home monitoring, Leuko aims to improve clinical outcomes for >2M cancer chemotherapy patients a year in the US and Europe, reduce their chemotherapy-related hospital readmissions by 50% and save >$6B annually in healthcare cost. Leuko is currently preparing its clinical trial for regulatory approval and expects product launch by 2025.